Benjamin et al. reported 12/25 CR/CRi rate for relapsed/refractory B-ALL patients receiving TRAC + CD52 KO anti-CD19 (9/12 MRD negative), all from the patients in the group that received alemtuzumab [226]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.